<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>Generate Core Safety Tables for Clinical Study Reports — AET01_table • dtlg</title><!-- favicons --><link rel="icon" type="image/png" sizes="96x96" href="../favicon-96x96.png"><link rel="icon" type="”image/svg+xml”" href="../favicon.svg"><link rel="apple-touch-icon" sizes="180x180" href="../apple-touch-icon.png"><link rel="icon" sizes="any" href="../favicon.ico"><link rel="manifest" href="../site.webmanifest"><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/Nunito-0.4.10/font.css" rel="stylesheet"><link href="../deps/Inconsolata-0.4.10/font.css" rel="stylesheet"><link href="../deps/Source_Sans_Pro-0.4.10/font.css" rel="stylesheet"><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet"><link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet"><script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Generate Core Safety Tables for Clinical Study Reports — AET01_table"><meta name="description" content="AET01_table() produces and combines the main safety summary tables
typically found in Section 14.3.1 of a Clinical Study Report (CSR). It
calculates patient counts and event totals for deaths, AE-related
withdrawals, total AEs, and adverse events of special interest (AESIs)."><meta property="og:description" content="AET01_table() produces and combines the main safety summary tables
typically found in Section 14.3.1 of a Clinical Study Report (CSR). It
calculates patient counts and event totals for deaths, AE-related
withdrawals, total AEs, and adverse events of special interest (AESIs)."></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-none" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">dtlg</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.0.2</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item"><a class="nav-link" href="../reference/index.html">Reference</a></li>
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-articles" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Articles</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-articles"><li><a class="dropdown-item" href="../articles/benchmarks.html">benchmarks</a></li>
  </ul></li>
<li class="nav-item"><a class="nav-link" href="../news/index.html">Changelog</a></li>
      </ul><ul class="navbar-nav"><li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json"></form></li>
      </ul></div>


  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1>Generate Core Safety Tables for Clinical Study Reports</h1>

      <div class="d-none name"><code>AET01_table.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p><code>AET01_table()</code> produces and combines the main safety summary tables
typically found in Section 14.3.1 of a Clinical Study Report (CSR). It
calculates patient counts and event totals for deaths, AE-related
withdrawals, total AEs, and adverse events of special interest (AESIs).</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">AET01_table</span><span class="op">(</span></span>
<span>  <span class="va">adsl</span>,</span>
<span>  <span class="va">adae</span>,</span>
<span>  <span class="va">patient_var</span>,</span>
<span>  <span class="va">treat_var</span>,</span>
<span>  <span class="va">aesi_vars</span>,</span>
<span>  aesi_heading <span class="op">=</span> <span class="st">"Total number of patients with at least one"</span>,</span>
<span>  indent <span class="op">=</span> <span class="st">"  "</span></span>
<span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>


<dl><dt id="arg-adsl">adsl<a class="anchor" aria-label="anchor" href="#arg-adsl"></a></dt>
<dd><p>A subject-level dataset (typically ADaM ADSL).</p></dd>


<dt id="arg-adae">adae<a class="anchor" aria-label="anchor" href="#arg-adae"></a></dt>
<dd><p>A dataset of adverse events, preprocessed with AESI flags.</p></dd>


<dt id="arg-patient-var">patient_var<a class="anchor" aria-label="anchor" href="#arg-patient-var"></a></dt>
<dd><p>A string indicating the subject identifier variable (e.g., <code>"USUBJID"</code>).</p></dd>


<dt id="arg-treat-var">treat_var<a class="anchor" aria-label="anchor" href="#arg-treat-var"></a></dt>
<dd><p>A string indicating the treatment arm variable (e.g., <code>"ARM"</code>).</p></dd>


<dt id="arg-aesi-vars">aesi_vars<a class="anchor" aria-label="anchor" href="#arg-aesi-vars"></a></dt>
<dd><p>A character vector of binary AESI flags in <code>adae</code>.</p></dd>


<dt id="arg-aesi-heading">aesi_heading<a class="anchor" aria-label="anchor" href="#arg-aesi-heading"></a></dt>
<dd><p>Optional character string used as a heading in the AESI block.</p></dd>


<dt id="arg-indent">indent<a class="anchor" aria-label="anchor" href="#arg-indent"></a></dt>
<dd><p>A string used to indent AESI row labels (default is 2 spaces).</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    <p>A merged <code>data.table</code> summarising the main safety outcomes.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="va">AET01_summary</span> <span class="op">&lt;-</span> <span class="fu">AET01_table</span><span class="op">(</span></span></span>
<span class="r-in"><span>  adsl <span class="op">=</span> <span class="va">adsl</span>,</span></span>
<span class="r-in"><span>  adae <span class="op">=</span> <span class="va">aesi</span>,</span></span>
<span class="r-in"><span>  patient_var <span class="op">=</span> <span class="st">"USUBJID"</span>,</span></span>
<span class="r-in"><span>  treat_var <span class="op">=</span> <span class="st">"ARM"</span>,</span></span>
<span class="r-in"><span>  aesi_vars <span class="op">=</span> <span class="fu"><a href="https://rdrr.io/r/base/c.html" class="external-link">c</a></span><span class="op">(</span><span class="st">"FATAL"</span>, <span class="st">"SER"</span>, <span class="st">"SERWD"</span>, <span class="st">"SERDSM"</span>, <span class="st">"RELSER"</span>,</span></span>
<span class="r-in"><span>                <span class="st">"WD"</span>, <span class="st">"DSM"</span>, <span class="st">"REL"</span>, <span class="st">"RELWD"</span>, <span class="st">"RELDSM"</span>, <span class="st">"SEV"</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="fu"><a href="https://rdrr.io/r/base/print.html" class="external-link">print</a></span><span class="op">(</span><span class="va">AET01_summary</span><span class="op">)</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                          stats   A: Drug X</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>                                                         &lt;char&gt;      &lt;char&gt;</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  1:              Total number of patients with at least one AE 100 (74.6%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  2:                                        Total number of AEs         502</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  3:                                     Total number of deaths  25 (18.7%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  4: Total number of patients withdrawn from study due to an AE    3 (2.2%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  5:                 Total number of patients with at least one            </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  6:                                      AE with fatal outcome    5 (3.7%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  7:                                                 Serious AE  85 (63.4%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  8:            Serious AE leading to withdrawal from treatment    6 (4.5%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  9:       Serious AE leading to dose modification/interruption  36 (26.9%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 10:                                         Related Serious AE  64 (47.8%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 11:                    AE leading to withdrawal from treatment  20 (14.9%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 12:               AE leading to dose modification/interruption  63 (47.0%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 13:                                                 Related AE  86 (64.2%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 14:            Related AE leading to withdrawal from treatment   10 (7.5%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 15:       Related AE leading to dose modification/interruption  44 (32.8%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 16:                          Severe AE (at greatest intensity)  77 (57.5%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>     B: Placebo C: Combination</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>         &lt;char&gt;         &lt;char&gt;</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  1: 98 (73.1%)    103 (78.0%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  2:        480            604</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  3: 23 (17.2%)     22 (16.7%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  4:   6 (4.5%)       5 (3.8%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  5:                          </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  6:   5 (3.7%)       6 (4.5%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  7: 80 (59.7%)     87 (65.9%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  8:  12 (9.0%)       9 (6.8%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  9: 40 (29.9%)     47 (35.6%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 10: 52 (38.8%)     64 (48.5%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 11: 24 (17.9%)     26 (19.7%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 12: 70 (52.2%)     77 (58.3%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 13: 85 (63.4%)     92 (69.7%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 14:   9 (6.7%)      12 (9.1%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 15: 44 (32.8%)     51 (38.6%)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span> 16: 70 (52.2%)     79 (59.8%)</span>
<span class="r-in"><span></span></span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p>Developed by Max Ebenezer-Brown, Max Norman, Xinye Li, Anja Peebles-Brown, Ramiro Magno.</p>
</div>

<div class="pkgdown-footer-right">

</div>

    </footer></div>





  </body></html>

